Phosphate-binder therapy: economical aspects


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Economical efficacy of phosphate-binder therapy in chronic kidney disease patients is discussed. Role of phosphate-binders in prevention of cardiovascular morbidity and mortality, as well as in decrease of frequency and duration of hospitalizations is discussed.

Толық мәтін

Рұқсат жабық

Авторлар туралы

N. Mikhailova

Әдебиет тізімі

  1. Mahon A. Epidemiology and classification of chronic kidney disease and management of diabetic nephropathy // Eur Endocr Rev. — 2006: 33—36.
  2. Foley R.N., Parfrey P.S. Cardiovascular disease and mortality in ESRD // J Nephrol. — 1998; 2: 239-245.
  3. Levey A.S., Andreoly S.P., DuBose T. et al. Chronic kidney disease: common, harmful and treatable: World Kidney Day 2007 // Pediatr Nephrol. — 2007;22:321-325.
  4. ERA-EDTA Daily congress news. — Issue 2/may 19, 2013. Р. 14.
  5. De Vecchi A.F., Dratwa M., Wiedemann M.E. Healthcare systems and endstage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies //Nephrol. Dial. Transplant. — 1999;14 Suppl 6:31—41.
  6. National Institute for Clinical Excellence. Final Appraisal Determination: The clinica and cost-effectiveness of home compared with hospital haemodialysis for patients with end-stage renal failure. http://www.nice.org.uk. 2007
  7. Михайлова Н.А. Значение фосфатбиндеров в лечении минеральных и костных нарушений при хронической болезни почек с учетом центральной роли нарушения гомеостаза фосфора в их формировании: обзор литературы // Клиническая нефрология. — 2013;1:64-70.
  8. White C.A., Jaffey J., Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients // Kidney Int. — 2007;71:312—317.
  9. Savica V., Calo L.A., Monardo P. et al. Phosphate binders and management of hyperphosphataemia in end-stage renal disease // Nephrol. Dial. Transplant. — 2006;21: 2065—2068.
  10. Rayner H.C., Pisoni R.L., Bommer J. et al. Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS) // Nephrol. Dial. Transplant. — 2004;19:108-120.
  11. A.C. Covic. Magnesium — beneficial effects over & above phosphate binding: ERA-EDTA Congress, Prague, 2011, 25 June, Industry Sponsored Simposium.
  12. Qunibi W.Y., Hootkins R.E., McDowell L.L. et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study) // Kidney Int. — 2004;65: 1914—1926.
  13. De Francisco A.L.M., Leidig M., Covic A.C. et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability // Nephrol Dial Transplant. — 2010;25:3707—3717.
  14. Deuber H.J. Long-term efficacy and safety of an oral phosphate binder containing both calcium and magnesium carbonate in hemodialysis patients // Nieren- und Hochdruckkrankheiten. — 2004;33:403—408.
  15. Huybrechts K.F., Caro J.J., Wilson D.A. et al. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis // Value. Health. — 2005;8:549—561.
  16. Qunibi W. Y., Moustafa M., Kessler P. et al. Coronary artery calcification (CAC) in Hemodialysis Patients (HDP):preliminary results fromteh Calcium Acetate Renagel Evaluation-2 (CARE-2) Study. American Society of Nephrology. — 2006.
  17. Brophy D.F., Wallace J.F., Kennedy D.T. et al. Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia // Pharmacotherapy. — 2000;20:950—957.
  18. Navaneethan S.D., Palmer S.C., Craig J.C. et al. Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials // Am J Kidney Dis. — 2009;54:619—637.
  19. Tonelli M., Pannu N., Manns B. Oral Phosphate Binders in Patients with Kidney Failure // N Engl J Med. — 2010;362:1312-1324.
  20. Tzanakis I.P., Wei M. Magnesium carbonate for phosphate control in patients on hemodialysis: A randomized controlled trial // Int Urol Nephrol. — 2008;40:193—201.
  21. Spiegel D.M., Farmer B. Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: A pilot study // Hemodial Int. — 2009;13:453—459.
  22. Manns B., Stevens L., Miskulin D. et al. Systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States // Kidney Int. — 2004;66:1239—1247.
  23. Peter W. St., Liu J., Fan Q. et al. DCOR Study: Assessing impact of sevelamer vs calcium binders on hospitalization & morbidity in hemodialysis patients using CMS data: Poster presentation. 2006.
  24. Bellucci G., Alessandri M., Buracchi P. et al. Serum Magnesium concentration and serum prathormone in hemodialysis patients // Ital J Mineral Electrolyte Metab. — 1998;12:77-79.
  25. Suki W., Zabaneh R., Cangiano J. et al. A Prospective Randomized Trial Assessing the Impact on Outcomes of Sevelamer in Dialysis Patients: The DCOR Trial. — American Society of Nephrology. — 2005.
  26. Block G.A., Raggi P., Bellasi A. et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients // Kidney Int. — 2007;71:438—441.
  27. Young E.W. Dialysis Outcomes & Practice Patterns Study (DOPPSII, 2002— 2004) // J.Am.Soc Nephrol. — 16.2005.
  28. Manns B., Klarenbach S., Lee H. et al. Economic evaluation of sevelamer in patients with end-stage renal disease // Nephrol.Dial.Transplant. — 2007.
  29. Suki W.N., Zabaneh R., Cangiano J.L. et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients // Kidney Int. — 2007.
  30. Peter W. St., Liu J., Fan Q. et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data // Am J Kidney Dis. — 2008;51:445-454.
  31. Peter W. St., Liu J., Fan Q. et al. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data // Clin J Am Soc Nephrol. — 2009;12:1954—1961.
  32. Cangialose C., Yeh Y., Pelham R. et al. The economics of phosphate binders in renal dialysis: a two stage strategy for managing hyperphosphatemia // Value Health. — 2003;6:198.
  33. Brennan A., Akehurst R., Davis S. et al. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease // Value Health. — 2007;10:32—41.
  34. Plagemann T., Prenzler A., Mittendorf T. Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia // Health Economics Review. — 2011;1:1—14.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>